Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Charles Makin"'
Autor:
Evelien Bergrath, Robert A. Gerber, David Gruben, Tatjana Lukic, Charles Makin, Gene Wallenstein
Publikováno v:
International Journal of Rheumatology, Vol 2017 (2017)
Objective. To compare the efficacy and tolerability of tofacitinib, an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), as monotherapy and combined with disease-modifying antirheumatic drugs (DMARDs) versus biological DMARD
Externí odkaz:
https://doaj.org/article/21c782550cd24a0c8dea63f818a34c3b
Autor:
Mitch Dekoven MHSA, Charles Makin BSPharm, MS, MBA, MM, Samantha Slaff MS, Michael Marcus MAS, Eric M. Maiese PhD
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 15 (2016)
Objective: To estimate health care costs associated with medical events identified as antiretroviral therapy (ART)-attributable adverse events (AEs). Methods: During September 2006 to June 2012, adults with ≥1 HIV International Classification of Di
Externí odkaz:
https://doaj.org/article/6f90b3927a794269aecb9001b27f9649
Autor:
Alberto Ferreira, Alexandros Sagkriotis, Melvin Olson, Jingsong Lu, Charles Makin, Fran Milnes
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0133968 (2015)
To compare treatment patterns of intravitreal ranibizumab and aflibercept for the management of neovascular age-related macular degeneration (nAMD) in a real-world setting over the first 12 months of treatment.A proprietary clinical database was used
Externí odkaz:
https://doaj.org/article/de53f06486d84880a9d31e44e58db49e
Autor:
Niklas Bergvall, Charles Makin, Raquel Lahoz, Neetu Agashivala, Ashish Pradhan, Gorana Capkun, Allison A Petrilla, Swapna U Karkare, Catherine Balderston McGuiness, Jonathan R Korn
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e88472 (2014)
BACKGROUND: Approximately one-third of patients with multiple sclerosis (MS) are unresponsive to, or intolerant of, interferon (IFN) therapy, prompting a switch to other disease-modifying therapies. Clinical outcomes of switching therapy are unknown.
Externí odkaz:
https://doaj.org/article/18de3690ffd14259ab1dc2230cda78cd
Publikováno v:
Journal of medical economics. 24(1)
Alzheimer's disease (AD) is the predominant cause of dementia and a leading cause of death globally. With no cure or treatment to slow disease progression, AD-related healthcare costs are substantial and increase as the severity of the disease progre
Autor:
Jason P. Mendoza, Ray Su, Anthony T. Reder, Megan Vignos, Nancy Arndt, Robin Avila, Caroline Geremakis, Cortnee Roman, Charles Makin
Publikováno v:
Multiple Sclerosis and Related Disorders. 51:102935
Multiple disease-modifying therapies (DMTs) have been approved by the U.S. FoodDrug Administration for the treatment of relapsing-remitting multiple sclerosis (RRMS). In separately conducted clinical trials, peginterferon beta-1a, subcutaneous interf
Autor:
Charles Makin, Heather F. Burnett, Wei Cheng, Xuan Li, Gabriel Tremblay, Ronda Copher, Patricia Guyot
Publikováno v:
Journal of comparative effectiveness research. 7(3)
Aim: For dichotomous outcomes, odds ratio (OR) is one of the usual summary measures of indirect treatment comparison. A corresponding number needed to treat (NNT) estimate may facilitate understanding of the treatment effect. Methods: We show how to
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 15 (2016)
Objective: To estimate health care costs associated with medical events identified as antiretroviral therapy (ART)-attributable adverse events (AEs). Methods: During September 2006 to June 2012, adults with ≥1 HIV International Classification of Di
Publikováno v:
Neurology and Therapy
Introduction Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder in children/adolescents and occurs frequently with psychiatric/neurologic comorbidities. The objective of this study was to assess the impact of psychiatric
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25ce34d01fc252de4373fc9a1cd331c4
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-146059
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-146059
Autor:
Tatjana Lukic, Evelien Bergrath, Gene V. Wallenstein, Robert A. Gerber, David Gruben, Charles Makin
Publikováno v:
International Journal of Rheumatology, Vol 2017 (2017)
International Journal of Rheumatology
International Journal of Rheumatology
Objective. To compare the efficacy and tolerability of tofacitinib, an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), as monotherapy and combined with disease-modifying antirheumatic drugs (DMARDs) versus biological DMARD